(Q39775919)

14 September 2017

title

Effect of decorin on overcoming the extracellular matrix barrier for oncolytic virotherapy (English)

1 reference

14 September 2017

0 references

1 reference

9

1 reference

14 September 2017

I-K Choi

1

1 reference

14 September 2017

Y-S Lee

2

1 reference

14 September 2017

J Y Yoo

3

1 reference

14 September 2017

A-R Yoon

4

1 reference

14 September 2017

H Kim

5

1 reference

14 September 2017

D-S Kim

6

1 reference

14 September 2017

D G Seidler

7

1 reference

14 September 2017

J-H Kim

8

1 reference

14 September 2017

language of work or name

1 reference

12 November 2009

1 reference

14 September 2017

1 reference

14 September 2017

volume

17

1 reference

14 September 2017

issue

2

1 reference

14 September 2017

page(s)

190-201

1 reference

https://scigraph.springernature.com/pub.10.1038/gt.2009.142

14 September 2017

exact match

0 references

cites work

Cancer gene therapy: hard lessons and new courses

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.142

Gene therapy for cancer: what have we done and where are we going?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.142

Recent progress in the battle between oncolytic viruses and tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.142

An adenovirus mutant that replicates selectively in p53-deficient human tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.142

Evaluation of E1B gene-attenuated replicating adenoviruses for cancer gene therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.142

Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.142

Replication-selective virotherapy for cancer: Biological principles, risk management and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.142

Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.142

Intratumoral spread of wild-type adenovirus is limited after local injection of human xenograft tumors: virus persists and spreads systemically at late time points

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.142

Pretreatment with protease is a useful experimental strategy for enhancing adenovirus-mediated cancer gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.142

Pre-treatment with elastase improves the efficiency of percutaneous adenovirus-mediated gene transfer to the arterial media

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.142

Specific inhibition of type I and type II collagen fibrillogenesis by the small proteoglycan of tendon

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.142

Negative regulation of transforming growth factor-beta by the proteoglycan decorin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.142

Targeted disruption of decorin leads to abnormal collagen fibril morphology and skin fragility

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.142

Differential interactions of decorin and decorin mutants with type I and type VI collagens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.142

Regulatory approvals of pediatric oncology drugs: previous experience and new initiatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.142

Transforming growth factor-beta regulation of immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.142

Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.142

Transforming growth factor-beta controls development, homeostasis, and tolerance of T cells by regulatory T cell-dependent and -independent mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.142

ADP-overexpressing adenovirus elicits enhanced cytopathic effect by induction of apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.142

Markedly enhanced cytolysis by E1B-19kD-deleted oncolytic adenovirus in combination with cisplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.142

21 January 2018

Gene therapy for cancer

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.142

7 January 2021

Wild-type adenovirus decreases tumor xenograft growth, but despite viral persistence complete tumor responses are rarely achieved--deletion of the viral E1b-19-kD gene increases the viral oncolytic effect

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.142

7 January 2021

Relaxin expression from tumor-targeting adenoviruses and its intratumoral spread, apoptosis induction, and efficacy

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.142

7 January 2021

Critical role of glutamate in a central leucine-rich repeat of decorin for interaction with type I collagen

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.142

7 January 2021

Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.142

7 January 2021

Identifiers

DOI

10.1038/GT.2009.142

1 reference

14 September 2017

1 reference